Skip to content
ppharmaranks
Menu
Class IIITerminated

Digoxin Tablets recall

FDA recall D-0389-2024 · initiated Mar 4, 2024

By the pharmaranks editorial teamReviewed against the FDA (openFDA) sourcesUpdated Mar 27, 2024How we research

Novitium Pharma LLC recalled Digoxin Tablets in Mar 2024 — an FDA Class III recall (D-0389-2024) because Cross Contamination with Other Products:(mycophenolate mofetil).

Unlikely to cause harm but violates FDA labeling or manufacturing regulations.

Why it was recalled

Cross Contamination with Other Products:(mycophenolate mofetil).

Something got into the product

A physical or chemical contaminant was found — glass or metal fragments, or a solvent that should not be there.

This is a manufacturing or quality failure, not a finding that the medicine is unsafe to take — across every recall we hold, none was issued for that reason. It does not mean the batch was harmless.

Is your product affected? Check the lot number

A recall covers only specific lots. Find the lot number and expiration date on your package and compare them to the affected codes below — if yours is not listed, it was not part of this recall.

Lot #: M23172A, Exp 01/31/2025

Quantity recalled: 3,940 1000-count bottles

Details

Product
Digoxin Tablets, USP 125mcg, (0.125 mg), 1000-count bottle, Rx Only, Manufactured by: Novitium Pharma LLC., 70 Lake Drive, East Windsor, New Jersey 08520, NDC 70954-201-20
Recalling company
Novitium Pharma LLC
Classification
Class III
Status
Terminated
Type
Voluntary: Firm initiated
Distribution
Nationwide in the USA
Initiated
Mar 4, 2024
FDA report date
Mar 27, 2024
What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.

Frequently asked

Was Digoxin Tablets recalled?
Novitium Pharma LLC recalled Digoxin Tablets in Mar 2024 — an FDA Class III recall (D-0389-2024) because Cross Contamination with Other Products:(mycophenolate mofetil). Unlikely to cause harm but violates FDA labeling or manufacturing regulations.
Why was Digoxin Tablets recalled?
Per the FDA enforcement record, the reason for recall D-0389-2024 was: Cross Contamination with Other Products:(mycophenolate mofetil).
Is a recalled Digoxin Tablets dangerous to take?
An FDA recall removes specific lots from the market for a defined reason and does not by itself mean the medicine is unsafe for everyone — your specific lot may never have been affected. Unlikely to cause harm but violates FDA labeling or manufacturing regulations. Check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This reproduces public FDA data and is not medical advice.
Which lots of Digoxin Tablets are affected?
Distributed: Nationwide in the USA. The recall covers these lots — Lot #: M23172A, Exp 01/31/2025. Check the lot number and expiration date on your package against this list; if yours is not listed, it was not part of recall D-0389-2024.

Source: openFDA Drug Enforcement record D-0389-2024

← All drug recalls